Evaluating the Role of Fluorodeoxyglucose PET Imaging in the Management of Patients with Sarcoidosis

PET Clinics

Volumn 1, Issue 2, 2006, Pages 141-152

  Yu, Jian Q ^a   Zhuang, Hongming ^b   Mavi, Ayse ^c   Alavi, Abass ^c  

^a FOX CHASE CANCER CENTER   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33846411569     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2006.01.002     Document Type: Review

References (78)

1. Hutchinson J. Case of livid papillary psoriasis. Illustrations of clinical surgery (1877), J&A Churchill, London 42
2. Muller-Quernheim J. Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J 12 (1998) 716-738
3. Rybicki B.A., Major M., Popovich Jr. J., et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 145 (1997) 234-241
4. Revsbech P. Is sarcoidosis related to exposure to pets or the housing conditions? A case-referent study. Sarcoidosis 9 (1992) 101-103
5. Baughman R.P., Shipley R., and Eisentrout C.E. Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis. Lung 165 (1987) 371-377
6. Line B.R., Hunninghake G.W., Keogh B.A., et al. Gallium-67 scanning to stage the alveolitis of sarcoidosis: correlation with clinical studies, pulmonary function studies, and bronchoalveolar lavage. Am Rev Respir Dis 123 (1981) 440-446
7. Beaumont D., Herry J.Y., Sapene M., et al. Gallium-67 in the evaluation of sarcoidosis: correlations with serum angiotensin-converting enzyme and bronchoalveolar lavage. Thorax 37 (1982) 11-18
8. Schoenberger C.I., Line B.R., Keogh B.A., et al. Lung inflammation in sarcoidosis: comparison of serum angiotensin-converting enzyme levels with bronchoalveolar lavage and gallium-67 scanning assessment of the T lymphocyte alveolitis. Thorax 37 (1982) 19-25
9. Braude A.C., Chamberlain D.W., and Rebuck A.S. Pulmonary disposition of gallium-67 in humans: concise communication. J Nucl Med 23 (1982) 574-576
10. Braude A.C., Cohen R., Rahmani R., et al. An in vitro gallium-67 lung index for the evaluation of sarcoidosis. Am Rev Respir Dis 130 (1984) 783-785
11. Tada A. [67-Gallium whole body scintigraphy and single photon emission computed tomography (SPECT) in sarcoidosis]. Nippon Rinsho 60 (2002) 1753-1758 [in Japanese]
12. Schuster D.M., and Alazraki N. Gallium and other agents in diseases of the lung. Semin Nucl Med 32 (2002) 193-211
13. Shorr A.F., Helman D.L., Lettieri C.J., et al. Depreotide scanning in sarcoidosis: a pilot study. Chest 126 (2004) 1337-1343
14. Lebtahi R., Crestani B., Belmatoug N., et al. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis. J Nucl Med 42 (2001) 21-26
15. Alavi A., Gupta N., Alberini J.L., et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med 32 (2002) 293-321
16. El-Haddad G., Zhuang H., Gupta N., et al. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med 34 (2004) 313-329
17. Zhuang H., and Alavi A. 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 32 (2002) 47-59
18. Zhuang H., Yu J.Q., and Alavi A. Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am 43 (2005) 121-134
19. Yu J.Q., Kung J.W., Potenta S., et al. Chronic cholecystitis detected by FDG-PET. Clin Nucl Med 29 (2004) 496-497
20. Yu J.Q., Zhuang H., Xiu Y., et al. Demonstration of increased FDG activity in Rosai-Dorfman disease on positron emission tomography. Clin Nucl Med 29 (2004) 209-210
21. Yu J.Q., Kumar R., Xiu Y., et al. Diffuse FDG uptake in the lungs in aspiration pneumonia on positron emission tomographic imaging. Clin Nucl Med 29 (2004) 567-568
22. Kung J., Zhuang H., Yu J.Q., et al. Intense fluorodeoxyglucose activity in pulmonary amyloid lesions on positron emission tomography. Clin Nucl Med 28 (2003) 975-976
23. Hughes J.M., Rhodes C.G., Brudin L.H., et al. Contribution of the positron camera to studies of regional lung structure and function. Eur J Nucl Med 13 Suppl (1987) S37-S41
24. Lewis P.J., and Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 35 (1994) 1647-1649
25. Alavi A., Buchpiguel C.A., and Loessner A. Is there a role for FDG PET imaging in the management of patients with sarcoidosis?. J Nucl Med 35 (1994) 1650-1652
26. Larson S.M. Cancer or inflammation? A Holy Grail for nuclear medicine. J Nucl Med 35 (1994) 1653-1655
27. Yasuda S., Shohtsu A., Ide M., et al. High fluorine-18 labeled deoxyglucose uptake in sarcoidosis. Clin Nucl Med 21 (1996) 983-984
28. Muggia F.M., and Conti P.S. Seminoma and sarcoidosis: a cause for false positive mediastinal uptake in PET?. Ann Oncol 9 (1998) 924
29. Kiatboonsri C., Resnick S.C., Chan K.M., et al. The detection of recurrent sarcoidosis by FDG-PET in a lung transplant recipient. West J Med 168 (1998) 130-132
30. Gotway M.B., Storto M.L., Golden J.A., et al. Incidental detection of thoracic sarcoidosis on whole-body 18-fluorine-2-fluoro-2-deoxy-D-glucose positron emission tomography. J Thorac Imaging 15 (2000) 201-204
31. Joe A., Hoegerle S., and Moser E. Cervical lymph node sarcoidosis as a pitfall in F-18 FDG positron emission tomography. Clin Nucl Med 26 (2001) 542-543
32. Xiu Y., Yu J.Q., Cheng E., et al. Sarcoidosis demonstrated by FDG PET imaging with negative findings on gallium scintigraphy. Clin Nucl Med 30 (2005) 193-195
33. Brudin L.H., Valind S.O., Rhodes C.G., et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 21 (1994) 297-305
34. Knopp M.V., and Bischoff H.G. [Evaluation of pulmonary lesions with positron emission tomography]. Radiologe 34 (1994) 588-591 [in German]
35. Kobayashi A., Shinozaki T., Shinjyo Y., et al. FDG PET in the clinical evaluation of sarcoidosis with bone lesions. Ann Nucl Med 14 (2000) 311-313
36. Dubey N., Miletich R.S., Wasay M., et al. Role of fluorodeoxyglucose positron emission tomography in the diagnosis of neurosarcoidosis. J Neurol Sci 205 (2002) 77-81
37. Ludwig V., Fordice S., Lamar R., et al. Unsuspected skeletal sarcoidosis mimicking metastatic disease on FDG positron emission tomography and bone scintigraphy. Clin Nucl Med 28 (2003) 176-179
38. Yamagishi H., Shirai N., Takagi M., et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med 44 (2003) 1030-1036
39. Cook G.J., Fogelman I., and Maisey M.N. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 26 (1996) 308-314
40. Lodge M.A., Lucas J.D., Marsden P.K., et al. PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 26 (1999) 22-30
41. Zhuang H., Pourdehnad M., Lambright E.S., et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 42 (2001) 1412-1417
42. Kubota K., Itoh M., Ozaki K., et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 28 (2001) 696-703
43. Aoki J., Watanabe H., Shinozaki T., et al. FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses. Skeletal Radiol 32 (2003) 133-138
44. Aoki J., Watanabe H., Shinozaki T., et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 219 (2001) 774-777
45. Cremerius U., Wildberger J.E., Borchers H., et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients. Urology 54 (1999) 900-904
46. de Hemricourt E., De Boeck K., Hilte F., et al. Sarcoidosis and sarcoid-like reaction following Hodgkin's disease. Report of two cases. Mol Imaging Biol 5 (2003) 15-19
47. Grunwald F., Schomburg A., Bender H., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 23 (1996) 312-319
48. Higashi K., Ueda Y., Sakuma T., et al. Comparison of [(18)F]FDG PET and (201)Tl SPECT in evaluation of pulmonary nodules. J Nucl Med 42 (2001) 1489-1496
49. Kalff V., Hicks R.J., Ware R.E., et al. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 43 (2002) 492-499
50. Karapetis C.S., Strickland A.H., Yip D., et al. PET and PLAP in suspected testicular cancer relapse: beware sarcoidosis. Ann Oncol 12 (2001) 1485-1488
51. Kubota K., Yamada S., Kondo T., et al. PET imaging of primary mediastinal tumours. Br J Cancer 73 (1996) 882-886
52. Nguyen A.T., Akhurst T., Larson S.M., et al. PET scanning with (18)F 2-fluoro-2-deoxy-D-glucose (FDG) in patients with melanoma. Benefits and limitations. Clin Positron Imaging 2 (1999) 93-98
53. Pitman A.G., Hicks R.J., Kalff V., et al. Positron emission tomography in pulmonary masses where tissue diagnosis is unhelpful or not possible. Med J Aust 175 (2001) 303-307
54. Pitman A.G., Hicks R.J., Binns D.S., et al. Performance of sodium iodide based (18)F-fluorodeoxyglucose positron emission tomography in the characterization of indeterminate pulmonary nodules or masses. Br J Radiol 75 (2002) 114-121
55. van der Hoeven J.J., Krak N.C., Hoekstra O.S., et al. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 22 (2004) 1253-1259
56. Maeda J., Ohta M., Hirabayashi H., et al. False positive accumulation in 18F fluorodeoxyglucose positron emission tomography scan due to sarcoid reaction following induction chemotherapy for lung cancer. Jpn J Thorac Cardiovasc Surg 53 (2005) 196-198
57. Yao M., Funk G.F., Goldstein D.P., et al. Benign lesions in cancer patients: case 1. Sarcoidosis after chemoradiation for head and neck cancer. J Clin Oncol 23 (2005) 640-641
58. Milman N., Mortensen J., and Sloth C. Fluorodeoxyglucose PET scan in pulmonary sarcoidosis during treatment with inhaled and oral corticosteroids. Respiration (Herrlisheim) 70 (2003) 408-413
59. Hain S.F., and Beggs A.D. C-11 methionine uptake in granulomatous disease. Clin Nucl Med 29 (2004) 585-586
60. Halter G., Buck A.K., Schirrmeister H., et al. [18F]3-deoxy-3′-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?. J Thorac Cardiovasc Surg 127 (2004) 1093-1099
61. Yamada Y., Uchida Y., Tatsumi K., et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med 39 (1998) 1160-1166
62. Oriuchi N., Inoue T., and Tomiyoshi K. F-19-fluro-alpha-methyltyrosine (FMT) and F-18-flurodeoxyglucose (FDG) PET in patients with sarcoidosis. J Nucl Med 40 (1999) 878
63. Smedema J.P., Truter R., de Klerk P.A., et al. Cardiac sarcoidosis evaluated with gadolinium-enhanced magnetic resonance and contrast-enhanced 64-slice computed tomography. Int J Cardiol (2005)
64. Smedema J.P., Snoep G., van Kroonenburgh M.P., et al. Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest 128 (2005) 30-35
65. Smedema J.P., Snoep G., van Kroonenburgh M.P., et al. The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. Chest 128 (2005) 1629-1637
66. Smedema J.P., Snoep G., van Kroonenburgh M.P., et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 45 (2005) 1683-1690
67. Mana J. Nuclear Imaging. 67 Gallium, 201 thallium, 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography. Clin Chest Med 18 (1997) 799-811
68. Okayama K., Kurata C., Tawarahara K., et al. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest 107 (1995) 330-334
69. Goto K., Okamoto E., Morita M., et al. [Cardiac sarcoidosis detected by FDG-PET]. Nippon Naika Gakkai Zasshi 94 (2005) 1396-1398 [in Japanese]
70. Ishimaru S., Tsujino I., Takei T., et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 26 (2005) 1538-1543
71. Okumura W., Iwasaki T., Toyama T., et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 45 (2004) 1989-1998
72. Smedema J.P., van Erven L., Schreur J.H., et al. [Cardiac sarcoidosis: improved prognosis through new diagnostic tests and treatment]. Ned Tijdschr Geneeskd 149 (2005) 1168-1173 [in Dutch]
73. Kaku B., Kanaya H., Horita Y., et al. Failure of follow-up gallium single-photon emission computed tomography and fluorine-18-fluorodeoxyglucose positron emission tomography to predict the deterioration of a patient with cardiac sarcoidosis. Circ J 68 (2004) 802-805
74. Stern B.J. Neurological complications of sarcoidosis. Curr Opin Neurol 17 (2004) 311-316
75. Braido F., Zolezzi A., Stea F., et al. Bilateral Gasser's ganglion sarcoidosis: diagnosis, treatment and unsolved questions. Sarcoidosis Vasc Diffuse Lung Dis 22 (2005) 75-77
76. Sponsler J.L., Werz M.A., Maciunas R., et al. Neurosarcoidosis presenting with simple partial seizures and solitary enhancing mass: case reports and review of the literature. Epilepsy Behav 6 (2005) 623-630
77. Abril A., and Cohen M.D. Rheumatologic manifestations of sarcoidosis. Curr Opin Rheumatol 16 (2004) 51-55
78. Aberg C., Ponzo F., Raphael B., et al. FDG positron emission tomography of bone involvement in sarcoidosis. AJR Am J Roentgenol 182 (2004) 975-977